Literature DB >> 30056547

Local and whole-body staging in patients with primary breast cancer: a comparison of one-step to two-step staging utilizing 18F-FDG-PET/MRI.

Julian Kirchner1, Johannes Grueneisen2, Ole Martin3, Mark Oehmigen4, Harald H Quick4,5, Ann-Kathrin Bittner6, Oliver Hoffmann6, Marc Ingenwerth7, Onofrio Antonio Catalano8, Philipp Heusch3, Christian Buchbender3, Michael Forsting2, Gerald Antoch3, Ken Herrmann9, Lale Umutlu2.   

Abstract

OBJECTIVES: The purpose of this study was to compare the diagnostic value of a one-step to a two-step staging algorithm utilizing 18F-FDG PET/MRI in breast cancer patients.
METHODS: A total of 38 patients (37 females and one male, mean age 57 ± 10 years; range 31-78 years) with newly diagnosed, histopathologically proven breast cancer were prospectively enrolled in this trial. All PET/MRI examinations were assessed for local tumor burden and metastatic spread in two separate reading sessions: (1) One-step algorithm comprising supine whole-body 18F-FDG PET/MRI, and (2) Two-step algorithm comprising a dedicated prone 18F-FDG breast PET/MRI and supine whole-body 18F-FDG PET/MRI.
RESULTS: On a patient based analysis the two-step algorithm correctly identified 37 out of 38 patients with breast carcinoma (97%), while five patients were missed by the one-step 18F-FDG PET/MRI algorithm (33/38; 87% correct identification). On a lesion-based analysis 56 breast cancer lesions were detected in the two-step algorithm and 44 breast cancer lesions could be correctly identified in the one-step 18F-FDG PET/MRI (79%), resulting in statistically significant differences between the two algorithms (p = 0.0015). For axillary lymph node evaluation sensitivity, specificity and accuracy was 93%, 95 and 94%, respectively. Furthermore, distant metastases could be detected in seven patients in both algorithms.
CONCLUSION: The results demonstrate the necessity and superiority of a two-step 18F-FDG PET/MRI algorithm, comprising dedicated prone breast imaging and supine whole-body imaging, when compared to the one-step algorithm for local and whole-body staging in breast cancer patients.

Entities:  

Keywords:  Local breast staging; PET/MRI; Supine breast PET/MRI

Mesh:

Substances:

Year:  2018        PMID: 30056547     DOI: 10.1007/s00259-018-4102-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  39 in total

1.  Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.

Authors:  Lino M Sawicki; Johannes Grueneisen; Benedikt M Schaarschmidt; Christian Buchbender; James Nagarajah; Lale Umutlu; Gerald Antoch; Sonja Kinner
Journal:  Eur J Radiol       Date:  2015-12-19       Impact factor: 3.528

Review 2.  Integrated PET/MR.

Authors:  Harald H Quick
Journal:  J Magn Reson Imaging       Date:  2013-12-12       Impact factor: 4.813

3.  Integrated PET/MR imaging: automatic attenuation correction of flexible RF coils.

Authors:  René Kartmann; Daniel H Paulus; Harald Braun; Bassim Aklan; Susanne Ziegler; Bharath K Navalpakkam; Markus Lentschig; Harald H Quick
Journal:  Med Phys       Date:  2013-08       Impact factor: 4.071

4.  Improved diagnostic accuracy with multiparametric magnetic resonance imaging of the breast using dynamic contrast-enhanced magnetic resonance imaging, diffusion-weighted imaging, and 3-dimensional proton magnetic resonance spectroscopic imaging.

Authors:  Katja Pinker; Wolfgang Bogner; Pascal Baltzer; Stephan Gruber; Hubert Bickel; Benedikt Brueck; Siegfried Trattnig; Michael Weber; Peter Dubsky; Zsuzsanna Bago-Horvath; Rupert Bartsch; Thomas H Helbich
Journal:  Invest Radiol       Date:  2014-06       Impact factor: 6.016

5.  Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.

Authors:  Leonardo Pace; Emanuele Nicolai; Angelo Luongo; Marco Aiello; Onofrio A Catalano; Andrea Soricelli; Marco Salvatore
Journal:  Eur J Radiol       Date:  2013-11-23       Impact factor: 3.528

6.  Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast.

Authors:  Onofrio Antonio Catalano; Dania Daye; Alberto Signore; Carlo Iannace; Mark Vangel; Angelo Luongo; Marco Catalano; Mazzeo Filomena; Luigi Mansi; Andrea Soricelli; Marco Salvatore; Niccolo Fuin; Ciprian Catana; Umar Mahmood; Bruce Robert Rosen
Journal:  Int J Oncol       Date:  2017-05-19       Impact factor: 5.650

7.  The impact of FDG-PET/CT on the management of breast cancer patients with elevated tumor markers and negative or equivocal conventional imaging modalities.

Authors:  Vasiliki Filippi; Joulia Malamitsi; Fani Vlachou; Fotios Laspas; Evangelos Georgiou; Vasileios Prassopoulos; John Andreou
Journal:  Nucl Med Commun       Date:  2011-02       Impact factor: 1.690

8.  Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.

Authors:  C Riegger; J Herrmann; J Nagarajah; J Hecktor; S Kuemmel; F Otterbach; S Hahn; A Bockisch; T Lauenstein; G Antoch; T A Heusner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-06       Impact factor: 9.236

9.  Accuracy of 18F-FDG PET/CT for primary tumor visualization and staging in T1 breast cancer.

Authors:  Bas B Koolen; Femke van der Leij; Wouter V Vogel; Emiel J Th Rutgers; Marie-Jeanne T F D Vrancken Peeters; Paula H M Elkhuizen; Renato A Valdés Olmos
Journal:  Acta Oncol       Date:  2013-05-14       Impact factor: 4.089

10.  Intraoperative Supine Breast MR Imaging to Quantify Tumor Deformation and Detection of Residual Breast Cancer: Preliminary Results.

Authors:  Eva C Gombos; Jagadeesan Jayender; Danielle M Richman; Diana L Caragacianu; Melissa A Mallory; Ferenc A Jolesz; Mehra Golshan
Journal:  Radiology       Date:  2016-06-22       Impact factor: 11.105

View more
  11 in total

1.  Determining the axillary nodal status with four current imaging modalities including 18F-FDG PET/MRI in newly diagnosed breast cancer: A comparative study using histopathology as reference standard.

Authors:  Janna Morawitz; Nils-Martin Bruckmann; Frederic Dietzel; Tim Ullrich; Ann-Kathrin Bittner; Oliver Hoffmann; Svjetlana Mohrmann; Lena Haeberle; Marc Ingenwerth; Lale Umutlu; Wolfgang Peter Fendler; Tanja Fehm; Ken Herrmann; Gerald Antoch; Lino Morris Sawicki; Julian Kirchner
Journal:  J Nucl Med       Date:  2021-05-20       Impact factor: 11.082

2.  microRNA-128-3p overexpression inhibits breast cancer stem cell characteristics through suppression of Wnt signalling pathway by down-regulating NEK2.

Authors:  Yuanwen Chen; Nian Wu; Lei Liu; Huaying Dong; Xinao Liu
Journal:  J Cell Mol Med       Date:  2020-06-17       Impact factor: 5.310

3.  A multiparametric [18F]FDG PET/MRI diagnostic model including imaging biomarkers of the tumor and contralateral healthy breast tissue aids breast cancer diagnosis.

Authors:  Doris Leithner; Joao V Horvat; Blanca Bernard-Davila; Thomas H Helbich; R Elena Ochoa-Albiztegui; Danny F Martinez; Michelle Zhang; Sunitha B Thakur; Georg J Wengert; Anton Staudenherz; Maxine S Jochelson; Elizabeth A Morris; Pascal A T Baltzer; Paola Clauser; Panagiotis Kapetas; Katja Pinker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-06-13       Impact factor: 9.236

4.  Prospective comparison of CT and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients: Initial results.

Authors:  Nils Martin Bruckmann; Julian Kirchner; Janna Morawitz; Lale Umutlu; Ken Herrmann; Ann-Kathrin Bittner; Oliver Hoffmann; Svjetlana Mohrmann; Marc Ingenwerth; Benedikt M Schaarschmidt; Yan Li; Andreas Stang; Gerald Antoch; Lino M Sawicki; Christian Buchbender
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.240

5.  Multiparametric 18F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.

Authors:  Lale Umutlu; Julian Kirchner; Nils-Martin Bruckmann; Janna Morawitz; Gerald Antoch; Saskia Ting; Ann-Kathrin Bittner; Oliver Hoffmann; Lena Häberle; Eugen Ruckhäberle; Onofrio Antonio Catalano; Michal Chodyla; Johannes Grueneisen; Harald H Quick; Wolfgang P Fendler; Christoph Rischpler; Ken Herrmann; Peter Gibbs; Katja Pinker
Journal:  Cancers (Basel)       Date:  2022-03-29       Impact factor: 6.575

Review 6.  The potential of predictive and prognostic breast MRI (P2-bMRI).

Authors:  Francesco Sardanelli; Pascal A T Baltzer; Matthias Dietzel; Rubina Manuela Trimboli; Moreno Zanardo; Rüdiger Schultz-Wendtland; Michael Uder; Paola Clauser
Journal:  Eur Radiol Exp       Date:  2022-08-22

7.  Multiparametric Integrated 18F-FDG PET/MRI-Based Radiomics for Breast Cancer Phenotyping and Tumor Decoding.

Authors:  Lale Umutlu; Julian Kirchner; Nils Martin Bruckmann; Janna Morawitz; Gerald Antoch; Marc Ingenwerth; Ann-Kathrin Bittner; Oliver Hoffmann; Johannes Haubold; Johannes Grueneisen; Harald H Quick; Christoph Rischpler; Ken Herrmann; Peter Gibbs; Katja Pinker-Domenig
Journal:  Cancers (Basel)       Date:  2021-06-11       Impact factor: 6.639

8.  Impact of 18F-FDG PET/MR on therapeutic management in high risk primary breast cancer patients - A prospective evaluation of staging algorithms.

Authors:  Julian Kirchner; Ole Martin; Lale Umutlu; Ken Herrmann; Ann-Kathrin Bittner; Oliver Hoffmann; Swetlana Mohrmann; Thomas Gauler; Sarah Theurer; Christina Antke; Irene Esposito; Sonja Kinner; Benedikt M Schaarschmidt; Bernd Kowall; Diana Lütke-Brintrup; Andreas Stang; Anton S Becker; Gerald Antoch; Christian Buchbender
Journal:  Eur J Radiol       Date:  2020-04-24       Impact factor: 4.531

9.  18F-FDG-PET/MRI in the diagnostic work-up of limbic encephalitis.

Authors:  Cornelius Deuschl; Theodor Rüber; Leon Ernst; Wolfgang P Fendler; Julian Kirchner; Christoph Mönninghoff; Ken Herrmann; Carlos M Quesada; Michael Forsting; Christian E Elger; Lale Umutlu
Journal:  PLoS One       Date:  2020-01-17       Impact factor: 3.240

10.  Prospective evaluation of whole-body MRI and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients.

Authors:  Nils Martin Bruckmann; Lino M Sawicki; Julian Kirchner; Ole Martin; Lale Umutlu; Ken Herrmann; Wolfgang Fendler; Ann-Kathrin Bittner; Oliver Hoffmann; Svjetlana Mohrmann; Frederic Dietzel; Marc Ingenwerth; Benedikt M Schaarschmidt; Yan Li; Bernd Kowall; Andreas Stang; Gerald Antoch; Christian Buchbender
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-04-24       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.